Novo Nordisk Top Five Sustainability Stories of 2014
In 2014 Novo Nordisk celebrated 10 years as a company with a Triple Bottom Line approach to business. These are the stories from 2014 that caught people's eye.
31 December, 2014, Bagsværd, Denmark /3BL Media/ - The readers have spoken! In 2014 Novo Nordisk celebrated 10 years as a company with a Triple Bottom Line approach to business. Throughout the year, Novo Nordisk shared stories and videos telling the actions and initiatives that demonstrate the company’s commitment to financial, environmental and social responsibility.
Here are the top five most read stores from Novo Nordisk’s sustainability communications.
1.The story of Novo Nordisk's Environmental Profit and Loss account
In February, Novo Nordisk became the first pharmaceutical company in the world to publish an Environmental Profit and Loss (E P&L) account. The results of the E P&L showed the total environmental costs related to water consumption, greenhouse gas (GHG) emissions, and air pollution, analysing how the company can manage risks and identify areas with potential for reductions.
The story behind the E P&L was told in an issue of Novo Nordisk’s sustainability magazine, TBL Quarterly, looking behind some of the company’s annual social and environmental performance numbers.
Read the full story here
2.Novo Nordisk 2013 Annual Report marks 10 years of integrated reporting
In February, Novo Nordisk published its 10th integrated annual report accounting for social, environmental and financial performance.
The 2013 report gave an update on the number of patients reached, job creation and employee engagement as well as CO2 emissions and water and energy consumption. It included articles on the global rise in diabetes, public trust in the pharmaceutical industry and the question of obesity as a disease.
2014 also marked the 10-year anniversary of the Triple Bottom Line in Novo Nordisk. In 2004, Novo Nordisk’s shareholders voted to amend the company’s Articles of Association to make the Triple Bottom Line an integral part of Novo Nordisk’s objectives.
Read the full story here
3. New model needed in diabetes care
In April, participants at the 5th International DAWN™ Summit (Diabetes Attitudes Wishes and Needs) pledged to work together to make person-centred diabetes care a reality for the 382 million people living with diabetes around the world.
Hosted by the International Diabetes Federation (IDF), the International Alliance of Patients’ Organizations (IAPO) and the Steno Diabetes Center and with support from Novo Nordisk, the DAWN™ Summit brought together over 200 leading experts, policymakers, researchers, clinicians and patient advocates from more than 30 countries to discuss policies, strategies, tools and best practices needed to enable partnership action to achieve this goal.
Read the full story here
4.Measuring the value of partnerships to change diabetes in India
In June, Novo Nordisk published its sixth business case in the ‘Blueprint for Change’ series demonstrating the shared value the company creates through its business activities. The case study shows how Novo Nordisk’s partnership approach in India is benefiting the healthcare system and helping to meet the treatment needs of people with diabetes.
The case study also explores how successful efforts can be scaled further across all India’s states and union territories with the Changing Diabetes® Barometer programme, a public-private partnership between state governments, Steno Diabetes Center and Novo Nordisk.
Read the full story here
5.Novo Nordisk brings one-stop diabetes care to African cities
In December, Novo Nordisk opened its eleventh Diabetes Support Centre, improving access to affordable diabetes treatment in some of the largest cities in Ghana and Nigeria. The centres are part of the company’s Base of the Pyramid project to help improve diabetes care and lessen the financial burden of diabetes treatment for low-income groups. They provide insulin and glucose testing equipment at a reduced cost, access to trained healthcare professionals and free diabetes screening for the general public.
The opening took place just a few weeks after it was announced that Novo Nordisk now ranks second on the 2014 Access to Medicine Index, climbing four places since the 2012 Index.
Read the full story here and here
Curious to know about the sustainability stories of 2015?
Stay updated on Novo Nordisk’s sustainability stories through our sustainability magazine, TBL Quarterly. If you would like to receive notifications when new issues are available, send a mail to sustainability@novonordisk.com.
Happy New Year and best wishes for a healthy and sustainable 2015!
About Novo Nordisk
Headquartered in Denmark, Novo Nordisk is a global healthcare company with more than 90 years of innovation and leadership in diabetes care. The company also has leading positions within haemophilia care, growth hormone therapy and hormone replacement therapy.
Novo Nordisk strives to conduct its activities in a financially, environmentally and socially responsible way. The strategic commitment to corporate sustainability has brought the company onto centre stage as a leading player in today’s business environment, recognised for its integrated reporting, stakeholder engagement and consistently high sustainability performance.
Visit Novo Nordisk Sustainability at www.novonordisk.com/sustainability
